Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer

Post time 2024-4-26 16:58:12

Edited by rsrib at 2024-4-26 18:23

journal：Annals of Oncology

Authors：W. Xie; P. Ravi; M. Buyse; S. Halabi; P. Kantoff; O. Sartor; H. Soule; N. Clarke; J. Dignam; N. James; K. Fizazi; S. Gillessen; N. Mottet; L. Murphy; W. Parulekar; H. Sandler; B. Tombal; S. Williams; C.J. Sweeney

Published date：2024-3-

DOI：10.1016/j.annonc.2023.11.017

PDF link：https://www.sciencedirect.com/sc ... 923753423051050/pdf

Article link：http://dx.doi.org/10.1016/j.annonc.2023.11.017

Article Source：Elsevier BV。

Remark：

Post time 2024-4-26 16:58:13

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer